CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new ...

Thank you for standing by for the Alphabet fourth quarter and fiscal year 2024 earnings conference call. At this time, all ...

During the Men’s and Women’s Snowboard SuperPipe finals on Thursday and Saturday, the system, which uses Google Cloud tools including Vertex AI ... shy of two months old, and organizers ...

Access to these treatments is provided under the terms of an interim commercial agreement reached between Vertex and NHS England ... children as young as two years old with cystic fibrosis will now be ...

British Watchmakers’ Day is held on Saturday 8 March 2025 at the Lindley Hall, London. There will be 2 sessions: 10am-2pm and 2pm-6pm. Free Club member tickets are now available to reserve for Club ...

Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.